See more : Atul Ltd (ATUL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Abbott Laboratories (ABT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abbott Laboratories, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Guangdong AVCiT Technology Holding Co., Ltd. (001229.SZ) Income Statement Analysis – Financial Results
- Guangxi Nanning Waterworks Co.,Ltd. (601368.SS) Income Statement Analysis – Financial Results
- Banco BTG Pactual S.A. (BPAC5.SA) Income Statement Analysis – Financial Results
- Torex Gold Resources Inc. (TORXF) Income Statement Analysis – Financial Results
- Royal Unibrew A/S (ROYUF) Income Statement Analysis – Financial Results
Abbott Laboratories (ABT)
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.11B | 43.65B | 43.08B | 34.61B | 31.90B | 30.58B | 27.39B | 20.85B | 20.41B | 20.25B | 21.85B | 39.87B | 38.85B | 35.17B | 30.77B | 29.53B | 25.91B | 22.48B | 22.34B | 19.68B | 19.68B | 17.68B | 16.29B | 13.75B | 13.18B | 12.48B | 11.88B | 11.01B | 10.01B | 9.16B | 8.41B | 7.85B | 6.88B | 6.16B | 5.38B | 4.94B | 4.39B | 3.81B | 3.36B |
| Cost of Revenue | 17.98B | 19.14B | 18.54B | 15.00B | 13.23B | 12.71B | 12.34B | 9.02B | 8.75B | 9.22B | 10.04B | 15.12B | 15.54B | 14.67B | 13.21B | 12.61B | 11.42B | 9.82B | 10.64B | 8.88B | 9.47B | 8.51B | 7.75B | 6.24B | 5.98B | 5.39B | 5.05B | 4.73B | 4.33B | 3.99B | 3.68B | 3.08B | 2.76B | 2.55B | 2.25B | 2.08B | 1.86B | 1.67B | 1.54B |
| Gross Profit | 22.13B | 24.51B | 24.54B | 19.61B | 18.67B | 17.87B | 15.05B | 11.83B | 11.66B | 11.03B | 11.81B | 24.75B | 23.31B | 20.50B | 17.56B | 16.92B | 14.49B | 12.66B | 11.70B | 10.80B | 10.21B | 9.18B | 8.54B | 7.51B | 7.20B | 7.08B | 6.84B | 6.28B | 5.69B | 5.16B | 4.72B | 4.77B | 4.12B | 3.60B | 3.13B | 2.85B | 2.53B | 2.14B | 1.82B |
| Gross Profit Ratio | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% | 58.45% | 54.96% | 56.73% | 57.13% | 54.47% | 54.05% | 62.08% | 60.00% | 58.30% | 57.06% | 57.29% | 55.92% | 56.33% | 52.36% | 54.86% | 51.86% | 51.90% | 52.42% | 54.61% | 54.64% | 56.77% | 57.54% | 57.03% | 56.79% | 56.38% | 56.18% | 60.81% | 59.85% | 58.53% | 58.19% | 57.82% | 57.65% | 56.17% | 54.19% |
| Research & Development | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.24B | 1.42B | 1.41B | 1.35B | 1.45B | 4.32B | 4.80B | 3.73B | 2.74B | 2.69B | 2.51B | 2.26B | 1.82B | 1.70B | 1.73B | 1.56B | 1.58B | 1.35B | 1.19B | 1.22B | 1.30B | 1.20B | 1.07B | 963.52M | 880.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -495.00K | -817.00K | -324.00K | 96.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.95B | 11.25B | 11.32B | 9.70B | 9.77B | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Other Expenses | 1.97B | 2.01B | 2.05B | 2.13B | 1.94B | 139.00M | 1.25B | -945.00M | 281.00M | -14.00M | 32.00M | 34.00M | -119.00M | 62.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -138.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -70.00M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| Operating Expenses | 15.66B | 16.15B | 16.11B | 14.25B | 14.14B | 14.22B | 13.33B | 8.64B | 8.79B | 8.43B | 9.18B | 16.38B | 17.56B | 14.10B | 11.15B | 11.12B | 9.91B | 8.60B | 7.32B | 6.62B | 6.78B | 5.54B | 5.31B | 4.11B | 4.05B | 3.97B | 3.99B | 3.66B | 3.30B | 3.02B | 2.80B | 3.25B | 2.56B | 2.20B | 1.91B | 1.75B | 1.52B | 1.26B | 1.08B |
| Cost & Expenses | 33.63B | 35.29B | 34.65B | 29.25B | 27.37B | 26.93B | 25.66B | 17.67B | 17.54B | 17.65B | 19.22B | 31.50B | 33.10B | 28.77B | 24.36B | 23.74B | 21.34B | 18.42B | 17.96B | 15.50B | 16.26B | 14.05B | 13.06B | 10.35B | 10.03B | 9.36B | 9.03B | 8.40B | 7.63B | 7.01B | 6.48B | 6.33B | 5.32B | 4.75B | 4.16B | 3.84B | 3.38B | 2.93B | 2.62B |
| Interest Income | 385.00M | 183.00M | 43.00M | 46.00M | 94.00M | 105.00M | 124.00M | 99.00M | 105.00M | 77.00M | 67.00M | 79.23M | 85.20M | 105.45M | 137.78M | 201.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 637.00M | 375.00M | 490.00M | 500.00M | 576.00M | 721.00M | 780.00M | 332.00M | 58.00M | 73.00M | 90.00M | 513.00M | 530.14M | 553.14M | 382.00M | 528.47M | 593.14M | 292.35M | 153.66M | 149.09M | 146.12M | 205.22M | 234.76B | 23.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B | 601.00M | 555.00M | 791.00M | 2.78B | 3.04B | 2.62B | 2.09B | 1.84B | 1.85B | 1.56B | 1.36B | 1.29B | 1.27B | 1.18B | 1.17B | 827.43M | 828.01M | 784.24M | 727.75M | 686.09M | 566.42M | 510.50M | 484.08M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| EBITDA | 10.61B | 12.38B | 12.74B | 8.79B | 7.77B | 7.12B | 6.13B | 3.07B | 4.83B | 4.22B | 3.45B | 3.50B | 9.26B | 9.14B | 9.49B | 8.22B | 6.43B | 4.25B | 6.22B | 5.61B | 4.20B | 4.30B | 4.39B | 3.40B | 3.98B | 3.90B | 3.56B | 3.30B | 2.95B | 2.65B | 2.41B | 1.95B | 1.94B | 1.76B | 1.53B | 1.37B | 1.25B | 1.08B | 892.90M |
| EBITDA Ratio | 26.44% | 24.50% | 24.95% | 21.94% | 20.87% | 19.51% | 18.08% | 13.38% | 18.37% | 15.51% | 15.80% | 21.08% | 15.08% | 19.30% | 20.82% | 21.20% | 25.41% | 33.72% | 23.92% | 27.28% | 21.54% | 25.87% | 33.77% | 26.56% | 27.68% | 29.46% | 28.54% | 29.05% | 29.16% | 28.61% | 27.38% | 21.50% | 27.41% | 28.02% | 27.53% | 27.03% | 28.27% | 27.62% | 24.92% |
| Operating Income | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.73B | 3.19B | 2.87B | 2.60B | 2.63B | 8.09B | 5.75B | 6.09B | 6.24B | 5.69B | 4.58B | 2.04B | 4.36B | 3.90B | 3.32B | 3.53B | 1.89B | 3.40B | 3.15B | 3.12B | 2.85B | 2.62B | 2.38B | 2.14B | 1.92B | 1.53B | 1.56B | 1.41B | 1.22B | 1.10B | 1.01B | 878.60M | 737.10M |
| Operating Income Ratio | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% | 11.94% | 6.30% | 15.27% | 14.05% | 12.84% | 12.03% | 20.28% | 14.81% | 17.31% | 20.27% | 19.28% | 17.67% | 9.09% | 19.53% | 19.81% | 16.88% | 19.96% | 11.63% | 24.74% | 23.90% | 24.99% | 23.99% | 23.76% | 23.80% | 23.42% | 22.88% | 19.43% | 22.64% | 22.83% | 22.70% | 22.32% | 22.92% | 23.07% | 21.94% |
| Total Other Income/Expenses | 186.00M | -56.00M | -214.00M | -389.00M | -455.00M | -777.00M | 667.00M | -1.61B | 316.00M | -81.00M | -92.00M | -1.22B | -553.36M | -374.75M | 958.03M | 162.45M | -108.90M | 234.15M | 257.65M | 227.28M | 411.89M | 143.27M | -10.88M | 415.83M | 247.53M | 123.98M | 84.17M | 52.44M | 12.42M | 22.48M | 19.26M | 212.80M | -12.80M | -55.30M | -27.00M | -46.60M | -68.50M | -59.90M | -42.60M |
| Income Before Tax | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B | 3.18B | 2.52B | 2.52B | 6.26B | 5.20B | 5.71B | 7.19B | 5.86B | 4.47B | 2.28B | 4.62B | 4.13B | 3.73B | 3.67B | 1.88B | 3.82B | 3.40B | 3.24B | 2.95B | 2.67B | 2.40B | 2.17B | 1.94B | 1.74B | 1.54B | 1.35B | 1.19B | 1.06B | 937.20M | 818.70M | 694.50M |
| Income Before Tax Ratio | 16.61% | 19.03% | 19.06% | 14.36% | 12.78% | 9.40% | 8.15% | 6.78% | 15.60% | 12.44% | 11.54% | 15.71% | 13.38% | 16.25% | 23.38% | 19.83% | 17.25% | 10.13% | 20.68% | 20.96% | 18.98% | 20.77% | 11.56% | 27.76% | 25.78% | 25.97% | 24.82% | 24.24% | 23.92% | 23.66% | 23.11% | 22.14% | 22.46% | 21.93% | 22.20% | 21.38% | 21.36% | 21.50% | 20.67% |
| Income Tax Expense | 941.00M | 1.37B | 1.14B | 497.00M | 390.00M | 539.00M | 1.88B | 350.00M | 577.00M | 797.00M | 138.00M | 300.00M | 470.00M | 1.09B | 1.45B | 1.12B | 863.33M | 559.62M | 1.25B | 949.76M | 981.18M | 879.71M | 332.76M | 1.03B | 951.13M | 907.37M | 855.48M | 787.52M | 706.62M | 650.01M | 544.10M | 499.70M | 455.50M | 385.00M | 334.40M | 303.40M | 304.60M | 278.20M | 229.20M |
| Net Income | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.40B | 4.42B | 2.28B | 2.58B | 5.96B | 4.73B | 4.63B | 5.75B | 4.88B | 3.61B | 1.72B | 3.37B | 3.24B | 2.75B | 2.79B | 1.55B | 2.79B | 2.45B | 2.33B | 2.08B | 1.88B | 1.69B | 1.52B | 1.40B | 1.24B | 1.09B | 965.80M | 859.80M | 752.00M | 632.60M | 540.50M | 465.30M |
| Net Income Ratio | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% | 21.68% | 11.28% | 11.79% | 14.95% | 12.17% | 13.15% | 18.68% | 16.53% | 13.92% | 7.64% | 15.10% | 16.44% | 13.99% | 15.80% | 9.52% | 20.27% | 18.56% | 18.71% | 17.50% | 17.09% | 16.87% | 16.56% | 16.64% | 15.78% | 15.83% | 15.68% | 15.98% | 15.23% | 14.42% | 14.20% | 13.85% |
| EPS | 3.30 | 3.94 | 3.97 | 2.52 | 2.07 | 1.35 | 0.27 | 0.95 | 3.00 | 1.51 | 1.66 | 3.78 | 3.01 | 2.99 | 3.72 | 3.16 | 2.34 | 1.12 | 2.17 | 2.07 | 1.76 | 1.79 | 1.00 | 1.80 | 1.59 | 1.52 | 1.35 | 1.21 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| EPS Diluted | 3.27 | 3.91 | 3.94 | 2.50 | 2.06 | 1.34 | 0.27 | 0.94 | 2.94 | 1.50 | 1.64 | 3.75 | 3.01 | 2.97 | 3.70 | 3.13 | 2.31 | 1.12 | 2.16 | 2.06 | 1.75 | 1.78 | 0.99 | 1.78 | 1.57 | 1.49 | 1.33 | 1.19 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| Weighted Avg Shares Out | 1.73B | 1.75B | 1.78B | 1.77B | 1.77B | 1.76B | 1.74B | 1.47B | 1.47B | 1.51B | 1.55B | 1.58B | 1.57B | 1.55B | 1.55B | 1.54B | 1.54B | 1.53B | 1.55B | 1.56B | 1.56B | 1.56B | 1.55B | 1.55B | 1.54B | 1.54B | 1.55B | 1.56B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
| Weighted Avg Shares Out (Dil) | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.56B | 1.56B | 1.56B | 1.54B | 1.56B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.56B | 1.56B | 1.58B | 1.58B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Abbott (ABT) closed at $115.59, marking a -0.33% move from the previous day.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Abbott (ABT) stood at $118.77, denoting a -0.15% change from the preceding trading day.
Growing EPD Business Supports ABT Stock Amid Macroeconomic Issues
Abbott has a unique opportunity to scale a capital-efficient licensing model that can help the emerging market population access life-changing medicines.
The Zacks Analyst Blog Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems
Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems are included in this Analyst Blog.
ABT Stock Benefits From First Patient Procedures With TAVI System
Abbott announces its investigational TAVI balloon-expandable system???s first patient procedures.
PAHC vs. ABT: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis
The investigational transcatheter aortic valve implantation (TAVI) system will complement Abbott's Navitor™ TAVI system for aortic stenosis, a common and life-threatening heart valve disease The investigational system is designed to offer best-in-class heart blood flow, ease of use and precision...
Abbott Laboratories: Investors Should Wait For A Pullback
Abbott has a very stable gross profit margin, while the company's revenue and return on invested capital could be more consistent. The company has increased their dividend for more than 50 years and should announce their 53rd dividend increase in...
Source: https://incomestatements.info
Category: Stock Reports